Salivary Antigen-5/CAP Family Members Are Cu²⁺-dependent Antioxidant Enzymes That Scavenge O₂⁻ and Inhibit Collagen-induced Platelet Aggregation and Neutrophil Oxidative Burst*

Teresa C. F. Assumpção¹, Dongying Ma¹, Alexandra Schwarz¹, Karine Reiter¹, Jaime M. Santana¹, John F. Andersen¹, José M. C. Ribeiro², Glenn Nardone²*, Lee L. Yu²*, and Ivo M. B. Francischetti²**

From the ¹Vector Biology Section, Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, Maryland, 20892, the ²Institute of Parasitology, Academy of Sciences of the Czech Republic, Biology Centre, 37005 Ceske Budejovice, Czech Republic, the ³Laboratory of Malaria Immunology and Vaccinology, NIAID, National Institutes of Health, Rockville, Maryland 20852, the ⁴Pathogen-Host Interface Laboratory, Department of Cell Biology, University of Brasilia, 70910-900 Brasilia, Brazil, the ⁵*Research Technology Branch, NIAID, National Institutes of Health, Rockville, Maryland 20852, and the ⁶**Chemical Sciences Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899-8391

Background: The function of most salivary antigen-5/CAP members has remained elusive for decades. Antigen-5/CAP family of proteins found in the salivary gland of bloodsucking animals has remained elusive for decades. Antigen-5/CAP members from the hematophagous insects *Dipetalogaster maxima* (DMAV) and *Triatoma infestans* (TIAV) were expressed and discovered to attenuate platelet aggregation, ATP secretion, and thromboxane A₂ generation by low doses of collagen (<1 μg/ml) but no other agonists. DMAV did not interact with collagen, glycoprotein VI, or integrin α₂β₁. This inhibitory profile resembles the effects of antioxidants Cu,Zn-superoxide dismutase (Cu,Zn-SOD) in platelet function. Accordingly, DMAV was found to inhibit cytochrome c reduction by O₂⁻ generated by the xanthine/xanthine oxidase, implying that it exhibits antioxidant activity. Moreover, our results demonstrate that DMAV blunts the luminescence signal of O₂⁻ generated by phorbol 12-myristate 13-acetate-stimulated neutrophils. Mechanistically, inductively coupled plasma mass spectrometry and fluorescence spectroscopy revealed that DMAV, like Cu,Zn-SOD, interacts with Cu²⁺, which provides redox potential for catalytic removal of O₂⁻. Notably, surface plasmon resonance experiments (BIACore) determined that DMAV binds sulfated glycosaminoglycans (e.g. heparin, Kᵋ ~100 nmol/liter), as reported for extracellular SOD. Finally, fractions of the salivary gland of *D. maxima* with native DMAV contain Cu²⁺ and display metal-dependent antioxidant properties. Antigen-5/CAP family of Cu²⁺-dependent antioxidant enzymes that inhibit neutrophil oxidative burst and negatively modulate platelet aggregation by a unique salivary mechanism.

The presence of anti-hemostatics in the salivary glands (SGs)³ of hematophagous animals is an evolutionary strategy aimed to decrease the inflammatory tonus that emerges at sites of insect bite (1). These responses comprise a series of complex biochemical reactions that ultimately prevent blood loss. In this respect, several anticoagulants, platelet inhibitors, and vasodilators have been identified in most salivary secretions studied to date (1). Notably, a remarkable diversity of mechanisms accounts for the anti-hemostatic properties of saliva. For example, platelet aggregation is blocked by apyrases or ADP-, TXA₂-, or serotonin-binding proteins; collagen inhibitors; integrin αβ₁ or αΙΙbβ₃ antagonists; cAMP or cGMP intra-platelet-in-

---

* This work was supported, in whole or in part, by National Institutes of Health Grant ZIA AI000810-16 and by the Intramural Research Program of the Division of Intramural Research, NIAID, National Institutes of Health. This work was also supported by and Brazilian grants from Fundacao de Amparo a Pesquisa do Distrito Federal, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, and Financiadora de Estudos e Projetos.

1 Supported by Grant Agency of the Czech Republic Grant P302/11/P798 and Ministry of Education, Youth, and Sports of the Czech Republic KONTAKT II Grant LH12002.

2 To whom correspondence should be addressed: Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, 12735 Twinbrook Pkwy., Rm. 2E-32C, Bethesda, MD 20852. Tel.: 301-402-2748; Fax: 301-480-2571; E-mail: ifrancischetti@niaid.nih.gov.

3 The abbreviations used are: SG, salivary gland; SGH, salivary gland homogenate; DMAV, *D. maxima* antigen-5; TIAV, *T. infestans* antigen-5; SOD, superoxide dismutase; MnTMPyP, manganese(III) tetrakis(1-methyl-4-pyridyl)porphyrin; ROS, reactive oxygen species; GPVII, glycoprotein VII; TXA₂, and TXB₂, thromboxane A₂ and B₂, respectively; PAF, platelet-activating factor; SEC, size exclusion chromatography; MALS, multilange light scattering; QELS, quasi-elastic light scatter detection; X/XO, xanthine/xanthine oxide; HBSS, Hanks’ buffered saline solution; cyt c, cytochrome c; PMA, phorbol 12-myristate 13-acetate; ICP-MS, inductively coupled plasma mass spectrometry; ITC, isothermal titration calorimetry; SPR, surface plasmon resonance; RU, response unit(s); PC/PS, phosphatidylycerine/phosphatidylcholine; DSS0K, 50,000-Da dextran sulfate; DSS50K, 500,000-Da dextran sulfate; Cvxx, convulxin.
A Novel Family of Salivary Platelet Inhibitors

creasing molecules (PGI₂, adenosine, and NO); anti-thrombins; and fibrinogenolytic enzymes (2).

Although the anti-hemostatic functions of several molecules in SGs are mediated by well known family of proteins, such as serpins, lipocalins, apyrases, and kazal and kunitz domain-containing molecules, several other inhibitors of platelet aggregation or coagulation cascade have not been characterized molecularly. More recently, transcriptome and proteome analysis (sialomes) of numerous SGs from hematophagous sources revealed that this tissue is a source of an unprecedented number of uniquely expressed proteins (e.g. 30-kDa allergens, yellow proteins, and antigen-5) (1, 3). Most often, the biological functions for members of these families have not been assigned. Notably, antigen-5 members, which belong to the CAP superfamily (cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins) of proteins, is inarguably one of the most, if not the most, ubiquitous family of salivary proteins, together with apyrases (3). The function of this family has remained elusive despite its presence in mosquitoes, sand flies, bugs, horse flies, Culicidae, Simulidae, ticks, and venomous animals (1). Only one salivary antigen-5 member has been unambiguously identified as an RGD-containing disintegrin by incorporation of a typical RGD triad flanked by cysteines not found in other antigen-5 members (4, 5).

In our attempt to identify the function of this family of proteins, we discovered that antigen-5 members from the SG of the Triatome vectors of Chagas disease, Dipetalogaster maxima (DMAV, D. maxima antigen-5) (6) and Triatoma infestans (TIAV, T. infestans antigen-5) (7) were inhibitors of low doses of collagen-induced platelet aggregation. DMAV did not interfere with aggregation triggered by other agonists or block the proximal interaction of collagen with platelets. This inhibitory profile resembles the inhibitory effects of antioxidants in platelet aggregation induced by collagen, which is the only agonist-promoting extracellular increase of O₂⁻ (8–11), in addition to intracellular reactive oxygen species (ROS). For example, blockade of extracellular O₂⁻ by N-acetylcysteine is accompanied by inhibition of low doses of collagen-induced platelet aggregation (12). In addition, Zn,Cu-SOD prevents platelet recruitment induced by collagen in vitro (10).

While the interplay of collagen and ROS has long been recognized (13–23), only more recently has it been explained molecularly (8, 9). Collagen interacts with GPVI, which signals by tyrosyl phosphorylation and NADPH oxidase activation through TRAF4 (24). These steps result in the generation of O₂⁻ that is critical to prime the cyclo-oxygenase enzyme for kinase activation (13, 24). Accordingly, intracellular O₂⁻ is important for collagen-induced platelet activation. NADPH oxidase inhibitor apocynin (12) or intracellular antioxidants, such as MnTMPyP, inhibit intracellular ROS formation by collagen and attenuate TXB₂ production and platelet aggregation (20). Furthermore, quercetin, which displays antioxidant properties, attenuates platelet aggregation by collagen (25).

Mechanistically, it was found that DMAV binds Cu²⁺ and catalytically removes O₂⁻. Therefore, this report is the first to determine the function of the antigen-5 family of salivary proteins as antioxidant enzymes. This discovery is important, given the wide expression of antigen-5 family members in bloodsucking animals, venomous creatures, and vertebrates (26). It also highlights the importance of scavenging O₂⁻ to attenuate the proinflammatory events associated with dysregulated production of ROS in the microcirculation.

EXPERIMENTAL PROCEDURES

Materials—Horse tendon insoluble Horm fibrillar collagen was from Chrono-Log Corp. (Haverstown, PA). Soluble collagen type I was from BD Biosciences. PGD₂, PGE₂, PGE₂a, PGD₂a, PGF₂a, PGH₂, endoperoxide mimetic (U-51605), PGI₂, cTXA₂, TXA₂ mimetic (U-46619), TXB₂, LTC₄, 5(S)-HETE, 9(S)-HETE, 15(S)-HETE, and 20-HETE were obtained from Cayman Chemicals (Ann Arbor, MI). ADP, norepinephrine, epinephrine, serotonin, indomethacin, PAF, and histamine were purchased from Sigma. Sensor CM5, amine-coupling reagents, and buffers were purchased from GE Healthcare. Heparin grade I-A from porcine intestinal mucosa (average molar mass 17–19 kDa; H3149), heparin grade II from porcine intestinal mucosa (H7005), heparan sulfate from bovine kidney (average molar mass 10–12 kDa; H7640), chondroitin sulfate C from shark cartilage (molar mass 50 kDa; C4384), dextran sulfate sodium from Leonostoc spp. (average molar mass 9–20 kDa; D6924), dextran sulfate 50K (Dextral50P) (average molar mass 50 kDa; D-8787), dextran sulfate 500K from Leonostoc spp. (average molar mass ≈ 500 kDa; D8906), lucigenin (3-aminophthalhydrazide; H-9377), xanthine oxidase (Grade III, 1–2 units/mg protein; 1.4 units/mg protein; 14 units/ml) from bovine milk (X4500), and Cu,Zn-SOD from bovine liver (S8409; 4,800 units/mg; 9,600 units/ml) were purchased from Sigma. Dextran (non-sulfated) standard 670 kDa (00896) and dextran (non-sulfated) standard 12 kDa (00270) were from Biochemica (Steinheim, Denmark). Enoxaparin (4,500 Da; 100 mg/ml) was from Sandoz (Princeton, NJ). Convulxin was purified as described (27), and GPVI was expressed as reported (28).

Sequence Analysis—Sequence similarity searches were performed using BLAST. Cleavage site predictions of the mature proteins used the SignalP program. The molar extinction coefficient (ε₂₈₀nm) of mature DMAV (gi344190589) at 280 nm was obtained using the ProtParam Web site, yielding a value of ε₂₈₀nm = 58,705 mol liter⁻¹ cm⁻¹ A₀.1% = 1.217, predicted molar mass 25,341 Da (224 amino acids), and isoelectric point (pl) 8.57.

Clustal Alignment and Phylogenetic Tree Construction—A sequence similarity search to DMAV was performed using protein BLAST against Arthropoda organisms with a low complexity region filter. The sequences derived from the nonredundant protein database of the National Center for Biotechnology Information (NCBI) are represented by five letters followed by the NCBI gi accession number. The five letters derive from the first three letters of the genus and the first two letters from the species name. The protein sequences were aligned by the ClustalX software program. The phylogenetic tree was created with the Mega package after 10,000 bootstrap with the neighbor-joining algorithm, using the p-dis-
A Novel Family of Salivary Platelet Inhibitors

Expression of DMAV and TIAV in Escherichia coli—All percentage concentrations are expressed as the volume fraction of the chemical in water. Synthetic cDNA for DMAV (gi 344190589) was produced by BioBasic Inc. (Markham, Canada). The sequence displays an N-terminal NdeI and a C-terminal XhoI restriction site. The Ndel site adds a 5’-methionine codon to all sequences that act as start codon in the bacterial expression system, whereas the XhoI site was incorporated after a stop codon. pET17b constructs were confirmed by sequencing before transformation by heat shock of E. coli strain BL21(DE3)pLysS cells. Cells were grown overnight in LB ampicillin/chloramphenicol agar plates, at 37 °C. Colonies were picked and then used to generate glycerol stocks (25% volume fraction). For recombinant protein production, a protocol similar to that described was employed (30). Briefly, 30 ml of Luria-Bertani broth (with 34 g/ml chloramphenicol and 100 μg/ml ampicillin) was inoculated and grown overnight for a maximum of 16 h at 37 °C. Luria-Bertani broth (1 liter with 34 μg/ml chloramphenicol and 100 μg/ml ampicillin) was inoculated with 10 ml of the overnight culture and grown at 37 °C with continuous shaking (26 rads/s) until an optical density of 0.6–0.8 (A600nm) was reached (~3 h). Isopropyl-1-thio-β-d-galac-topyranoside (1 mmol/liter) was added to induce expression, and the flask was shaken for 3 h under the same conditions; cells were harvested by centrifugation (6,000 × g, 20 min) and washed once in 20 mmol/liter Tris-HCl, pH 8.0, before the cell pellet was frozen and stored until use. Pellets were sonicated several times, washed in 20 mmol/liter Tris, pH 8.3, centrifuged, and finally resuspended in 25 ml of 20 mmol/liter Tris, pH 8.3, containing 6 mM guanidine and DTT (10 mmol/liter). After 1 h, the sample was centrifuged at 16,000 × g for 30 min. Twenty-five ml was added slowly, drop-by-drop, into 4 liters of refolding buffer (20 mmol/liter Tris, 0.3 mol/liter arginine, 1 mmol/liter EDTA, 1 mmol/liter reduced glutathione (GSH), and 0.2 mmol/liter oxidized glutathione (GSSG), pH 9.3) under agitation. After 2 days under agitation at 4 °C, the solution containing DMAV was concentrated to ~30 ml by tangential flow with a 10-kDa cut-off filter (Millipore, Inc., Billerica, MA). Sample was centrifuged (12,000 × g, 20 min) and concentrated to 30 ml in a Millipore ultrafiltration apparatus (membrane of 10 kDa). The sample was centrifuged (12,000 × g, 20 min), and the supernatant was used for protein purification (see below). Antigen-5 members from T. infestans (gi 149898844) were cloned in pET17b and expressed as above except that refolding was performed at pH 7.4. As a control, a lipocalin from D. maxima (DM146, gi 315270899) was cloned, expressed, and purified as above.

Protein Purification—DMAV (10 ml) was loaded into a HiPrep 16/60 Sephacryl S-100 HR (GE Healthcare) column connected to an AKTA purifier system (Amersham Biosciences) and equilibrated in 20 mmol/liter Tris-HCl, 0.15 mol/liter NaCl, pH 9.3, with a flow of 1 ml/min. Protein was detected by peak absorbance at 280 and 220 nm, and fractions containing DMAV (estimated by SDS-PAGE) were combined (4 ml) and concentrated in a Centricon concentrator (10 kDa cut-off). Samples were loaded in a gel filtration column (Superdex 75 HR10/30, Amersham Biosciences) equilibrated in 20 mmol/liter Tris-HCl, 0.5 mol/liter NaCl, pH 9.3. Elution was carried out at a flow rate of 1 ml/min, and fractions containing DMAV were combined. Fractions were dialyzed against 20 mmol/liter Tris-HCl and loaded in a Mono Q anion exchange column (Amersham Biosciences). To remove bacterial DNA potentially contaminating DMAV, the fractions containing DMAV were combined and dialyzed against 10 mmol/liter HEPES, pH 6.0, centrifuged, and loaded into cation exchange chromatography using a HiPrep 16/10 SP FF column (Amersham Biosciences). Proteins were eluted with a linear gradient of NaCl (0–1 mol/liter) over 60 min at a flow rate of 0.5 ml/min. Fractions containing DMAV were combined and dialyzed against PBS, pH 7.4. DMAV was also purified in a reversed-phase C-18 chromatography column (Vydac, Carpenteria, CA), with a 60-min linear gradient of acetonitrile and 0.1% TFA at a flow rate of 1 ml/min. PAGE and Edman degradation were performed as described (30).

Mass Spectrometry of Purified DMAV—DMAV molecular weight was determined with a Sciex 4000 Q Trap ESI mass spectrometer.

Circular Dichroism—To examine secondary structure, samples were diluted in 1 × PBS, CD spectra were recorded over the wavelength range 190–260 nm in a 1-mm path length quartz cuvette using a step size of 0.2 nm, a slit bandwidth of 1.0 nm, and a signal averaging time of 1.0 s using a Jasco J-815 circular dichroism spectrometer. Percentages of secondary structures were determined as described (31, 32).

SEC-MALS-QELS-HPLC—To assess the identity, purity, and solution aggregation state of purified DMAV (17 μmol/liter), analytical size exclusion chromatography (SEC) with in-line multiangle light scattering (MALS) and quasi-elastic light scatter detection (QELS) was performed. Chromatography was done on an Alliance HPLC system (Waters Corp., Milford MA) connected to a multangle DAWN EOS MALS detector and a QELS detector (Wyatt Technology, Santa Barbara, CA).

Spectrum of DMAV—Spectrum of DMAV (500 μl at 5 μmol/liter in TBS, pH 7.4) was analyzed by UV-visible spectroscopy wavelength scanning (Cary 100 BIO spectrophotometer; Varian Inc., Walnut Creek, CA) using the eluent buffer (TBS) as a blank. Aliquots of CuCl2 (in TBS, pH 7.4) were added in 10-μl increments, reaching a maximum concentration of 100 μmol/liter CuSO4.

Determination of Free Cysteine in DMAV—Reactions for thiol modification were done at room temperature in 100 μl of 20 mmol/liter Tris-HCl, pH 8.0, 1 mmol/liter 4-fluoro-7-amino-7-nitrosouleifobenzoazuran, 20% DMSO for 1 h. The reactions were read in a Tecan M200 plate reader at excitation and emission wavelengths of 386 and 516 nm, respectively. Reduction of DMAV was done with 10 mmol/liter TCEP at 40 °C for 20 min. Non-reducing protein denaturation was done in 0.1% volume fraction SDS at 60 °C for 30 min. In some experiments, DMAV was incubated with buffer or xanthine/xanthine oxidase (X/XO) followed by mass spectrometry (MS).

Anti-DMAV Polyclonal Antibody—Recombinant DMAV produced in E. coli was diluted to 1 mg/ml and injected in the presence of Freund’s adjuvant in rabbits at Spring Valley Laboratories (Woodbine, MD). Additional injections were per-
A Novel Family of Salivary Platelet Inhibitors

formed 3, 6, and 9 weeks later to boost the immune response. Before injection of DMAV, preimmune serum was obtained from all rabbits.

ELISA to Detect DMAV—Antibody titer was estimated by ELISA using bacterial expressed DMAV (0.5 μg/well) immobilized overnight in PBS at 4 °C. Wells were blocked with 200 μl of TBS-BSA (BSA (2%, w/v) in TBS) for 2 h and then incubated for 1 h with a serial dilution of anti-DMAV antibody in TBS-BSA-Tween (BSA, 1% volume fraction; Tween, 0.05% volume fraction in TBS). After washing four times with TBS-BSA-Tween, the wells were incubated with a 1:2,000 dilution of anti-rabbit alkaline phosphatase-coupled antibody for 1 h and washed four times with TBS-BSA-Tween. Two hundred μl of substrate (p-nitrophenyl phosphate liquid substrate system; Sigma) was added, and reactions were followed for 10 min and stopped with 100 μl of NaOH (0.375 mol/liter, final concentration). Absorbance was detected at 405 nm.

D. maxima Salivary Gland Purification—For some experiments, the supernatant from the homogenate obtained from 50 pairs of D. maxima (reared at the Institute of Parasitology, Biology Centre, Ceske Budejovice, Czech Republic) was applied to a Sephadex G-75 column, equilibrated with PBS, pH 7.4, at a flow rate of 0.5 ml/min.

Mass Spectrometry and Protein Identification—Samples from selected fractions obtained above were solubilized in NU/PAGE sample buffer containing DTT and loaded into a 4–12% NuPAGE gel with MES buffer (Invitrogen). The gel was cut in 20 slices of ~0.5 cm (from top to bottom of each lane), and identification was performed on reduced and alkylated, trypsin-digested samples prepared by standard MS protocols. The supernatant and two washes (5% formic acid in 50% acetonitrile) of the gel digests were pooled and concentrated by SpeedVac (Labconco, Kansas City, MO) to dryness directly in nitrile) of the gel digests were pooled and concentrated by SpeedVac (Labconco, Kansas City, MO) to dryness directly in nitrile)

Platelet Preparation, Aggregation, ATP Secretion, and TXA₂ Generation—Platelet-rich plasma was obtained under informed consent from medication-free platelet donors participating in a National Institutes of Health Institutional Review Board-approved protocol of the Department of Transfusion Medicine (DTM/NIH, Blood Bank). Platelet-rich plasma (100 μl) was added to 200 μl of Tyrode’s buffer (137 mmol/liter NaCl, 27 mmol/liter KCl, 12 mmol/liter NaHCO₃, 0.42 mmol/liter NaH₂PO₄, 1 mmol/liter MgCl₂, 5.55 mmol/liter Hepes, 0.25% bovine serum albumin, pH 7.4) giving a final concentration of 200,000–400,000 platelets/μl. Platelet aggregation was estimated using a Lumi-Aggregometer (Chrono-Log Corp.) under agitation as reported (30). In experiments using PGG₂, platelets were washed and resuspended in Tyrode’s buffer supplemented with gelatin (0.25% volume fraction). PAF was prepared as described (30). To estimate dense granule ATP release, peak luminescence was detected by adding luciferin-luciferase (20 μl) 4 min after the addition of collagen. For TXA₂ generation, platelets were activated by collagen, and after 4 min, the sample was transferred to an Eppendorf tube and centrifuged for 15 s at 14,000 × g. The supernatant was immediately frozen in dry ice, and then at ~80 °C. The next day, the sample was thawed and used at a 1:300 dilution for detection of TXB₂ by competitive ELISA (Cayman).

Platelet Adhesion—For platelet adhesion assays, platelet-rich plasma was incubated with calcein-AM (2 μmol/liter, Calbiochem) for 30 min at room temperature and centrifuged in the presence of EDTA (5 mmol/liter) and apyrase (0.2 units/ml). Platelets were resuspended (2 × 10⁷/μl) in Tyrode’s buffer (no additions). Inhibition of platelet adhesion to immobilized collagen was examined by fluorometry. Microfluor black microtiter 96-well plates (ThermoLabsystems, Franklin, MA) were coated with 50 μl (1 μg/well in PBS) of fibrillar (Horm) or soluble collagen I (BD Biosciences) overnight at 4 °C in PBS, pH 7.4. Wells were washed with PBS and blocked with 2% (w/v) BSA (in PBS). Calcein-labeled platelets (2 × 10⁵/μl) were incubated with DMAV or EDTA for 20 min, and 50 μl of platelets was added to each well. After 1 h, wells were washed three or four times with Tyrode-BSA, and adhesion was estimated by fluorescence (excitation 485 nm/emission 530 nm).

Thrombus Formation—Thrombus formation under flow was performed essentially as described (4).

Neutrophil Preparation—Polyprep medium (6.5 ml; MP Biomedicals, Solon, OH) was added to a 15-ml Falcon tube. Blood (7 ml, collected in 5 mmol/liter EDTA, final concentration) was carefully layered on the Polyprep medium. The tubes were centrifuged at 209 rads/s (863 × g), for 45 min using acceleration and deceleration set at 5, at room temperature. Two rings were observed; the upper ring was discarded, and the lower ring was
collected and transferred to a 50-ml Falcon tube. Then HBSS (Cellgro) (no calcium, no magnesium; 40 ml) was added, and cells were centrifuged again for 10 min at 104 rads/s. When contamination with red blood cells was visible, 1 ml of lysis buffer was added to the tubes for 40–50 s, followed by the addition of HBSS (45 ml) and centrifugation as above. The pellet was resuspended in 3 ml and counted, and concentration was adjusted to 2 × 10⁶/ml in HBSS (no Ca²⁺, no Mg²⁺). Cells were kept on ice.

O₂⁺ Production by Neutrophils—In 96-well Chromalux HB flat bottom white polystyrene microplates for luminescent applications (catalog no. 2010) (Diniz Technologies), neutrophils (50 µl at 1 × 10⁶/ml) were added to wells in the presence of DMAV (0–10 µl), followed by the addition of 50 µl of Diogenes reagent (National Diagnostics, Atlanta, GA) or 50 µl of lucigenin (20 µmol/liter, final concentration) or 50 µl of luminol (500 µmol/liter, final concentration) diluted in HBSS. Then 5–10 µl of PMA (10–20 nmol/liter, final concentrations) was added, and luminescence was read in an LMAX II³⁸⁴ Plate Luminometer (Molecular Devices, Sunnyvale, CA). Diogenes reagent was diluted as indicated by the manufacturer, whereas lucigenin (40 mmol/liter) and luminol (500 mmol/liter) were diluted in DMSO followed by extensive vortexing.

Xanthine Oxidase Generation of O₂⁺ Estimated by Luminol or Lucigenin—Fifty µl of reaction mixture (RM) (100 mmol/liter phosphate buffer, pH 7.8, 500 µmol/liter hypoxanthine, and 500 µmol/liter luminol; final concentrations) was added to the wells, followed by the addition of DMAV (0–10 µl). Reactions started with xanthine oxidase (50 µl, 1:2,500, or 1:5,000 final concentrations; ~5 milliunits/ml) using a multichannel pipette. Plates were immediately read using an LMAX II³⁸⁴ Luminometer (Molecular Devices), and integrations of the signal were obtained with Softmax Pro software. Results are expressed as luminescence estimated under the curve. Uric acid formation was estimated by the increase in UV absorbance at 293 nm. Phosphate buffer was prepared by mixing 90 mmol/liter Na₂HPO₄ and 10 mmol/liter NaH₂PO₄.

Reduction of Cytochrome c (cyt c)—In a 96-well flat microplate, 100 µl of RM (0.1 mol/liter phosphate buffer, 0.5 mmol/liter hypoxanthine, and 12.0 µM (0.15 mg/ml) cyt c, final concentrations) was added to the wells, followed by the addition of DMAV (0–3 µl). Reactions started by the addition of 10 µl of xanthine oxidase (1:2,500; ~5 milliunits/ml, final concentration). The reduction of cyt c was continuously detected at 550 nm using a Thermomax ELISA reader (Molecular Devices). For kinetic experiments, DMAV (10 µmol/liter) was incubated with saturating concentrations (20 µmol/liter) of Cu²⁺ or Zn²⁺, followed by extensive dialysis against PBS. To calculate the Kₗₑₜ of DMAV for O₂⁺, data were transformed as described (33).

Measurement of H₂O₂—Measurement of H₂O₂ was performed using Amplex Red reagent (Invitrogen) as described in the manufacturer’s instructions. Briefly, an RM was prepared containing 2.35 ml of Krebs-Ringer phosphate (145 mmol/liter NaCl, 5.7 mmol/liter sodium phosphate, 4.86 mmol/liter KCl, 0.54 mmol/liter CaCl₂, 1.22 mmol/liter MgSO₄, 5.5 mmol/liter glucose, pH 7.35), 50 µl of Amplex Red (50 µmol/liter), and 100 µl of horseradish peroxidase (HRP; 0.1 unit/ml). Then 50 µl of RM was added to 50 µl of neutrophils (0.5 × 10⁶/ml, final concentrations), followed by the addition of PMA (20 nmol/liter to 40 nmol/liter). When a cell-free system was used, 5 µl of hypoxanthine (500 µmol/liter final concentrations) was added to 50 µl of RM (which was diluted in HBSS), with and without DMAV. Reactions were started by the addition of 50 µl of XO (6.4 milliunits/ml to 12.8 milliunits/ml, final concentrations). As a control, Cu,Zn-SOD (0.4 milliunit/ml, final concentration) was tested. Reactions were followed with an excitation of 540 nm and emission of 590 nm using a SpectraMAX Gemini XPS Fluorimeter (Molecular Devices).

Measurement of O₂ Consumption—O₂ consumption was monitored at 25 °C using a Gilson 5/6 oxygraph fitted with a Clark electrode as described (33, 34). The electrode was calibrated for absolute O₂ concentration. Reactions were injected using a long tip into the reaction chamber under continuous agitation with a stir bar placed in the base of the chamber. The RM, in a final volume of 1.5 ml, typically contained 100 mmol/liter phosphate buffer, pH 7.8, 0.5 mmol/liter hypoxanthine, and 0.7 milliunit/ml xanthine oxidase. Consumption of O₂ was characterized by a deflection of the recorder. In some experiments, catalase (333 units/ml) or DMAV (0.5 µM) was added to the chamber.

Inductively Coupled Plasma Mass Spectrometry (ICP-MS)—Aqueous samples from DMAV obtained directly from the last purification step (cation exchange column) were extensively dialyzed (cut-off of 10 kDa, Slide-A-Lyzer, Thermo Scientific) against 5 mm Hepes, pH 7.4, and transferred into a 15-ml autosampler tube. The mass of the sample was weighed on a four-place analytical balance by difference. An aliquot of 5 g of diluent consisted of 1.5% volume fraction. Optima grade nitric acid (HNO₃; Fisher) in water was weighed into the tube. The diluted sample was thoroughly mixed by gentle shaking. The contents of the samples were analyzed using the SemiQuant mode of Agilent (Santa Clara, CA) model 7500cs inductively coupled plasma mass spectrometer. The sample introduction system of the mass spectrometer consisted of a PFA microflow (0.1 ml/min) concentric nebulizer, a PFA Scott type double-pass spray chamber, and a sapphire injector. The SemiQuant mode is capable of quantifying elements of the entire periodic table by using the spectral information of the elements. The instrument was calibrated using a solution containing 20 µg kg⁻¹ each of 31 elements (lithium, beryllium, boron, sodium, magnesium, aluminum, calcium, scandium, vanadium, chromium, manganese, cobalt, nickel, copper, zinc, arsenic, selenium, strontium, molybdenum, silver, cadmium, antimony, barium, lanthanum, europium, holmium, ytterbium, thallium, lead, thorium, and uranium) prepared by diluting catalog no. ICP-MS calibration standard (High Purity Standards, Charleston, SC) with 1.5% HNO₃. National Institute of Standards and Technology Standard Reference Material (SRM) 1643e, Trace Elements in Water, was measured with the samples. SRM 1643e served as the quality assurance for the measurement (35).

Reconstitution of DMAV with Divalent Ions and Detection by ICP-MS—Purified DMAV (8 ml, 10 µmol/liter, in PBS) was initially incubated with EDTA (20 mmol/liter) for 30 min and dialyzed against 2 liters of PBS, pH 7.4 (eight changes over 4 days). Then 1 ml of DMAV (10 µmol/liter) was incubated sep-
A Novel Family of Salivary Platelet Inhibitors

arately with 30 μmol/liter each of Cu2+, Mn2+, Ni2+, Co2+, and Zn2+ for 40 min, followed by extensive dialysis against 2 liters of Heps (2 mmol/liter), pH 7.4 (eight changes over 3 days). In the displacement assays, DMAV (10 μM) was incubated first with a mixture containing 15 μmol/liter each of Mn2+, Ni2+, Co2+, and Zn2+ for 40 min, followed by the addition of 15 μmol/liter Cu2+ and dialysis as above. In the competition assays, DMAV (10 μmol/liter) was incubated with a mixture of 15 μmol/liter each of Mn2+, Ni2+, Co2+, Zn2+, and Cu2+ for 40 min and dialyzed against 5 mM Heps, pH 7.4. One ml of each ion-DMAV complex was used for ICP-MS.

Fluorescence Spectroscopy—Spectroscopy was carried out in a Jasco J-815 fluorospectrophotometer. Trypophan fluorescence emissions were collected following excitation at 278 nm at a DMAV concentration of 20 μmol/liter in 1 ml of TBS, pH 7.4, using quartz cuvettes (1-cm light path). Solutions of 2 mmol/liter of CuSO4, ZnSO4, or Li2SO4 were prepared in TBS, by making successive injections of 10 μl each of the solutions in acetate buffer, pH 5.0, and dialyzed against 5 mM Heps, pH 7.4. Each salt was added in 1-μl increment aliquots, followed by emission scanning between 300 and 420 nm, with a maximum at 346 nm. Scanning was performed three times for each concentration, and the results were reported as the average for three runs. To calculate the apparent kDa, data points representing the fluorescence quenching values were fitted using non-linear regression using a single-site hyperbola model.

Isothermal Titration Calorimetry (ITC)—Prostanoids (in ethanol or methyl acetate) were placed in glass vials, and the vehicle was evaporated under a nitrogen atmosphere; the dried material was then resuspended in appropriate concentrations in 20 mmol/liter Tris-HCl, 0.15 mol/liter NaCl, pH 7.4, sonicated, and vortexed as described (30). Calorimetric assays for measuring DMAV binding to a number of ligands were performed using a VP-ITC microcalorimeter (Microcal, Northampton, MA) at 30 °C. Titration experiments were performed by making successive injections of 10 μl each of 40 μmol/liter ligand into the 1.34-ml sample cell containing 4 μmol/liter DMAV until near saturation was achieved. Prior to the run, the proteins were dialyzed against 20 mmol/liter Tris-HCl, 0.15 mol/liter NaCl, pH 7.4, for binding experiments. The calorimetric enthalpy (∆Hcal) for each injection was calculated after correction for the heat of the DMAV dilution obtained in control experiments performed by titrating DMAV into buffer. The binding isotherms were fitted according to a model for a single set of identical binding sites by nonlinear squares analysis using Micrcal Origin software (OriginLab, Northampton, MA).

Surface Plasmon Resonance (SPR)—All SPR experiments were carried out in a T100 instrument (Biacore Inc., Uppsala, Sweden) following the manufacturer’s instructions. For immobilization using an amine-coupling kit (Biacore), CM5 chips were activated with 1-ethyl-3-(dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide before injection of DMAV (10 μg/ml) in acetate buffer, pH 5.0. Remaining activated groups were blocked with 1 mol/liter ethanolamine, pH 8.5, resulting in a final immobilization of 593.7 RU. Kinetic experiments were carried out by injecting different glycans, 500,000-Da dextran sulfate (DS500K), 50,000-Da dextran sulfate (DS50K), heparin (20 kDa), and heparin sulfate (14 kDa), for a contact time of 120 s at a flow rate of 30 μl/min at 25 °C. For all runs, HBS-P buffer was used (10 mmol/liter HEPES, 150 mmol/liter NaCl, 0.005% surfactant P20, pH 7.4). DMAV-sulfated glycan complex dissociation was monitored for 600 s, and the sensor surface was regenerated by a pulse of 30 s of 1 mol/liter NaCl at 30 μl/min. For all experiments, blank flow cells were used to subtract the buffer effect on sensorgrams. After subtraction of the contribution of bulk refractive index and nonspecific interactions with the CM5 chip surface, the individual association (kₐ) and dissociation (kᵰ) rate constants were obtained by global fitting of data using interaction models (bivalent ligand or two-state reaction) using BIAevaluation™ (BIAcore AB, Uppsala, Sweden). Values were then used to calculate the equilibrium constant (Kₑ). Conditions were chosen so that the contribution of mass transport to the observed values of Kₑ was negligible. In addition, models in the T100 evaluation software fit for mass transfer coefficient to mathematically extrapolate the true kₐ and kᵰ. For some analytes (DS50 and DS500), the dissociation was too slow to calculate the dissociation rate constant, and the Kᵰ was calculated using affinity (steady-state) mode, which indicates concentration dependence binding at equilibrium levels. For some experiments, several sulfated glycans (diluted in HBS-P) were injected for 90 s with a dissociation time of 300 s. In some experiments, DMAV was used to interact with biotinylated heparin, immobilized as follows. Neutravidin (40 μg/ml; Pierce) in acetic buffer, pH 5.0, was immobilized in a CM5 chip for 7 min (10 μl/min), resulting in 2,000 RU, and blocked with ethanolamine. Then, biotinylated heparin (10 μg/ml in HBS-P; Sigma-Aldrich) was applied to the chip at a flow rate of 20 μl/min until it reached ~100 RU. DMAV was injected at a flow rate of 10 μl/min, with an association time of 30 s and dissociation time of 300 s. The chip was regenerated by a 30-s pulse with 1 mol/liter NaCl.

Interaction of DMAV with Heparin-Agarose—A HiTrap-heparin-HP column (5 ml; GE Healthcare) was connected to an AKTA purifier system (Amersham Biosciences). Before use, the column was extensively washed with 2 mol/liter NaCl. The column was then equilibrated with 10 mmol/liter Tris, 0.15 mol/liter NaCl (TBS) at a flow rate of 1 ml/min. DMAV (200 μl at 12.5 μmol/liter in TBS) was loaded into the column, followed by washing for 20 min with TBS. No increase in absorbance was observed in the flow-through. Then a 0–2 mol/liter NaCl gradient (in TBS) at 1 ml/min was performed for 40 min.

Interaction of DMAV with Phospholipid Vesicles and Platelet Membranes—DMAV (3 μmol/liter) was incubated with PC/PS (10 μmol/liter) in 10 mmol/liter TBS (pH 7.4) supplemented with CaCl₂ (5 mM). After 30 min, the mixture was centrifuged to separate pellet and supernatant. NuPAGE sample buffer containing 5% β-mercaptoethanol was added to the samples and loaded in a 4–12% NuPAGE gel. Gels were Coomassie Blue-stained. DMAV that had not been incubated with PC/PS was used as a control. In other experiments, washed platelets (resuspended in Tyrode’s buffer without BSA or gelatin) were incubated with PBS (control) or Horm collagen (10 μg/ml) for 4 min under agitation in a Lumi-Aggregometer in the presence or absence of DMAV. Pellet and supernatant were obtained as above. DMAV that had not been incubated with platelets was used as control.
A Novel Family of Salivary Platelet Inhibitors

Other Assays—Recalcification time, endothelial cell proliferation, vasodilation activity, and complement inhibition assays were performed exactly as described in detail previously (4, 30, 36).

Statistical Analysis—Results are expressed as mean ± S.E. (GraphPad Software, Inc., San Diego, CA). Statistical significance was set at p < 0.05 (t test or analysis of variance). For ICP-MS experiments, absolute expanded uncertainty for the results is 50% of the measured value, whereas the relative expanded uncertainty is 20% of the measured value for results of the same batch/measurement.

RESULTS

Antigen-5 Family of Salivary Proteins and Phylogenetic, Biochemical, and Biophysical Properties—Fig. 1A shows the alignment of antigen-5 family members from several bloodsucking arthropods. Most proteins are 20–25 kDa with distinct pl values containing four cysteines and four histidines, which are highly conserved at positions His52, His100, His160, and His215 (numbering system based on the sequence of DMAV). Other highly conserved clusters of amino acids are VGC and LVCNY. DMAV also exhibits a cluster of basic lysine residues in the C terminus, which may contribute to protein interaction with negatively charge molecules. Antigen-5 members belong to an expanded family of proteins from several blood-sucking arthropods whose phylogenetic associations are present in Fig. 1B.

To determine the function of the antigen-5 family of proteins, one member from D. maxima SGs was cloned, expressed, and refolded in a buffer containing 1 mmol/liter EDTA, 300 mmol/liter arginine, and oxidized and reduced glutathione at pH 9.3. The recombinant protein was purified through four chromatography steps, including two runs in gel filtration columns, one in an anion exchange column (Mono Q), and one in a cation exchange column (not shown). The purity of this preparation was assessed by one additional step in a reversed-phase column where only one peak was observed (not shown) and SDS-PAGE, which reveals one single band under denaturing or reducing conditions (Fig. 1C, inset). The N terminus of DMAV (MQXQNSQNFGLGSLEITGKYR) was determined by Edman degradation and is identical to the sequence predicted by the cDNA for the mature protein. The mass of the recombinant protein (25,337 Da) was also confirmed by tandem MS (Fig. 1C) and is compatible with the molecular mass as predicted by the cDNA (25,341 Da), with an additional methionine used for expression purposes.

Next, DMAV was examined by analytical SEC-MALS-QELS-HPLC to determine solution state, molar mass, and hydrodynamic radius. Analysis of DMAV by SEC-HPLC indicated that 100% of the protein was monomeric in solution with a retention time of 19.018 min (Fig. 1D). Further analysis of DMAV by in-line MALS indicated that the weight average molar mass, 28.8 kDa, of the monomeric peaks is similar to the theoretical mass of 25,341 kDa (Fig. 1D), suggesting a globular shape of the protein. To further characterize the tertiary structure of DMAV, the hydrodynamic radius (Rg) of the monomeric recombinant protein was examined by QELS. The Rg of DMAV was 2.8 nm, indicating that the monomeric form of the protein is globular-like. Next, CD spectra of DMAV were generated to examine its secondary structures, which were characterized by an increased intensity in negative ellipticity between 205 and 235 nm or decrease from 190 to 205 nm (Fig. 1E). Fig. 1E (inset) shows the percentage distribution of secondary structures in DMAV: α-helices (22.6 ± 4.8%), β-sheet (30.0 ± 4.4%), β-turn (16.1 ± 4.2%), and random (30.7 ± 4.8%).

DMAV was tested in a number of screening assays in an attempt to discover its function. DMAV (1 μmol/liter) did not prolong the recalcification time or interfere with endothelial cell proliferation. It did not produce vasodilation or inhibit the complement cascade (data not shown).

DMAV Specifically Inhibits Collagen-induced Platelet Aggregation—When tested in platelets, DMAV was found to inhibit collagen-induced platelet aggregation. The specificity of DMAV as a platelet aggregation inhibitor was then verified. Fig. 2A shows that only low doses (<1 μg/ml) of collagen-induced platelet aggregation are inhibited dose-dependently by DMAV. No effects on shape change were observed, suggesting that the inhibitor does not interfere with a proximal pathway of platelet activation (i.e. collagen-receptor interaction). It has also been noticed that platelets from some donors were more sensible to inhibition by DMAV than others. In addition, our results demonstrate that DMAV does not affect platelet aggregation by moderate to high doses of collagen or any concentration tested for a number of agonists, including convulxin, thrombin, arachidonic acid, TXA2/PGG2 mimetic U46619, native PGG2, PGH2, ADP, and PAF.

Because DMAV appears to be a specific inhibitor of collagen-induced platelet aggregation, we verified whether it blocks platelet-collagen interactions. Fig. 2B demonstrates that DMAV does not affect platelet adhesion to collagen (positive controls with EDTA). Surface plasmon resonance experiments also shows that DMAV does not interact with recombinant GPVI (positive control with convulxin) (Fig. 2C). Low doses of collagen-mediated platelet aggregation are particularly dependent on secondary mediators ADP and TXA2 or native PGG2/PGH2 (37). Whereas DMAV fails to block aggregation by these agonists, we also confirmed by ITC that DMAV does not bind to either ADP or cTXA2 (Fig. 2D). 12-H(P)ETE, a derivative of the 12-lipoxygenase that reportedly participates in platelet aggregation by collagen, also consistently failed to bind to DMAV. In addition, 26 other ligands, including U46619, TXB2, U51605, PGG2, PGF2α, PGD2, PGE2, PGE1, 8-iso-PGF2α, iloprost, 5(S)-HETE, 15(S)-HETE, 20-HETE, i-oleoyl-lyso-phosphatidic acid, sphingosine 1-phosphate, arachidonic acid, PAF, LTB4, LTC4, LTD4, LTE4, epinephrine, norepinephrine, histamine, and serotonin, tested negative for binding to DMAV (not shown). Together, these experiments suggested that DMAV affects platelets by a mechanism that is clearly distinct from other salivary inhibitors of collagen-induced platelet aggregation (2).

Antigen-5 Member from T. infestans Salivary Gland Also Inhibits Platelet Aggregation—Besides DMAV, a second member of the antigen-5 family was expressed from T. infestans (TIAV) in order to verify whether the anti-platelet function was conserved. Fig. 3A compares the SDS-PAGE for both DMAV and TIAV, which exhibits the expected molar masses. Fig. 3B demonstrates that TIAV inhibits platelet aggregation by low
A Novel Family of Salivary Platelet Inhibitors

A

B

C

D

E
doses of collagen (0.5 μg/ml). Because collagen, but not ADP or thrombin, is the only platelet agonist that consistently promotes an increase of extracellular $O_2^-$ (10, 11), it was hypothesized that antigen-5 members might affect the pro-aggregatory properties of ROS on platelets. Therefore, we compared the effects of TIAV with Cu,Zn-SOD. Fig. 3B also shows that Cu,Zn-SOD, like TIAV, attenuates platelet aggregation (but not the shape change) by collagen (0.5 μg/ml). On the other hand, arachidonic acid (58 μmol/liter)-induced aggregation is not affected by both inhibitors (Fig. 3C). We also tested the effects of TIAV in other parameters of platelet activation. Fig. 3D and E, demonstrate that TIAV dose-dependently inhibits platelet ATP secretion and TXA2 generation induced by collagen, respectively. Because it has been reported that NADPH oxidase inhibitors, such as diphenylene iodonium and apocynin, partially attenuate thrombus formation triggered by a collagen surface at high shear rates in vitro (38), we tested TIAV in this assay. Fig. 3F (left panel) shows thrombus formation in control experiments. In the presence of TIAV (3 μmol/liter; Fig. 3F, right panel), a slight effect could be observed in the shape of the thrombus; however, this effect was variable and dependent on the donor, being difficult to consistently quantify.

**DMAV Scavenges $O_2^-$**—Experiments with platelets supported the hypothesis that DMAV operates through scavenging of $O_2^-$. To test this, we employed PMA-stimulated neutrophils, which generate intense production of $O_2^-$ through activation of NADPH oxidases. Our results show that DMAV dose-dependently inhibits the signal due to $O_2^-$ when evaluated by either Diogenes reagent (Fig. 4A) or lucigenin (Fig. 4B) with I$_{50}$ of ~0.5 μmol/liter. We also tested the effects of DMAV in $O_2^-$ generated in a cell-free system by X/XO according to Reaction 1.

$$\text{XO}$$

$$\text{Hypoxanthine + O}_2 + \text{H}_2\text{O} \rightarrow \text{Uric acid + O}_2^- + \text{H}^+$$

**REACTION 1**

Fig. 4C demonstrates that DMAV diminishes the $O_2^-$ signal (detected by Luminol) with concentrations similar to those observed with neutrophils. In contrast, a number of other available recombinant salivary proteins expressed in *E. coli* (e.g., DM146, triplatin, SVEP, yellow protein) or in insect cells (e.g. ixolaris, 9.3 kDa) and purified as described for DMAV were ineffective in the same assay (Fig. 4D).

To confirm the antioxidant activity of DMAV using another detection method, we evaluated its effects in the cyt c reduction assay using X/XO to generate $O_2^-$ in vitro.

**Fig. 4E** demonstrates that DMAV produces partial inhibition of cyt c reduction, whereas three other recombinant proteins (ixolaris, dipetalodipin, and BSA) were without effect. We also determined that the enzymatic activity of X/XO, evaluated by production of uric acid, was unaffected by DMAV (Fig. 4F).

Altogether, it was hypothesized that DMAV operates either as a non-catalytic scavenger of $O_2^-$ (33) or as an enzyme (e.g. Cu,Zn-SOD) that could dismutate $O_2^-$ to $\text{H}_2\text{O}_2$ (39), according to Reactions 2 and 3, where M is metal.

$$M^{(n+1)^{\pm}} - \text{SOD} + O_2^- \rightarrow M^{n^{\pm}} - \text{SOD} + \text{O}_2$$

**REACTIONS 2 and 3**

To test whether DMAV also generates $\text{H}_2\text{O}_2$, peroxide production was estimated using Amplex Red reagent in reactions started with X/XO. In contrast to Cu,Zn-SOD, which increases $\text{H}_2\text{O}_2$ formation, DMAV did not increase its production (Fig. 4G).

DMAV was also tested to determine whether it works as a catalase according to Reaction 4.

$$2\text{H}_2\text{O}_2 \rightarrow 2\text{H}_2\text{O} + \text{O}_2$$

**REACTION 4**

An $\text{H}_2\text{O}_2$ standard curve was constructed, followed by incubation for 15 min with PBS or DMAV. $\text{H}_2\text{O}_2$ was detected with Amplex Red. Fig. 4H shows that no change in the concentration of $\text{H}_2\text{O}_2$ was observed. We aimed to determine whether DMAV displays catalase activity using a direct method using a Clark electrode, which measures oxygen concentration in a solution (33). In this experiment, the solution containing xanthine exhibited an oxygen concentration of ~280 μM. When XO was added to the chamber (under stirring conditions), the generation of $O_2^-$ was accompanied by consumption of $O_2^-$. Detectable by a continuous downward inflection of the pen (Fig. 4I). After 15 min, most $O_2$ that has been converted to $O_2^-$ will spontaneously dismutate to stable $\text{H}_2\text{O}_2$. Accumulation of $\text{H}_2\text{O}_2$ can be detected by the addition of catalase (control) to this solution, because conversion of $\text{H}_2\text{O}_2$ into $O_2$ and water produces an increase in $O_2$ levels according to Reaction 4, which is detected by a sharp upward inflection of the pen (Fig. 4I). When the experiments were performed as above but DMAV was added instead of PBS, no change in oxygen consumption was noticed. Furthermore, after the addition of catalase, the same change in $O_2^-$ formation was observed (relative to PBS), implying that DMAV is devoid of catalase activity.

**FIGURE 1. Characterization of DMAV.** A, Clustal alignment of DMAV (gi344190589) and antigen-5 members from T. infestans (TIAV; gi149898844), Rhodinus prolixus (RPAV; gi33518699), Aedes aegypti (AAAV; gi18568278), Drosophila melanogaster (DmAV; gi7292999), Culex quinquefasciatus (CQAV; gi83850629); Anopheles gambiaca (AGAV; gi118788028); Simulium nigrimanus (SNAV; gi269146468); Simulium vitatum (SVAV; gi197269688), Phlebotomus duboscqi (PDAV; gi112497675), and Lutzomyia longipalpis (LLAV; gi4887102). B, phylogenetic tree for antigen-5 family members from several blood sucking salivary glands. Two antigen-5 members studied herein are indicated as DMAV (*) or TIAV (#). C, purity of DMAV. An aliquot of purified DMAV was used for mass spectrometry and yielded a mass of 25,337 Da (predicted mass, 25,341 Da). Inset on the left, SDS-PAGE of DMAV. Three μg of DMAV under non-reducing (DTT-) or reducing (DTT+) conditions was applied to 4 –12% NuPAGE. Molecular weight markers are loaded in the same column, and elution volume was compared with DMAV (arrow, inset) (inline multianode light scatter). The solid and red lines represent absorbance 280 nm and MALS results, respectively. E, CD analysis of DMAV in aqueous solution. The ellipticity (degrees cm$^2$/dmol) was plotted as a function of wavelength (nm). Inset, percentage of secondary structures.
Proteins exhibit antioxidant activity through three distinct mechanisms (*i.e.* methionine oxidation (40), cysteine oxidation (41), and metal oxidation (39)). To verify whether free cysteines with the potential to scavenge O$_2^.$ are present in DMAV, the protein was incubated with benzofurazone 4-fluoro-7-amino-sulfonylbenzofurazan, which reacts with free cysteines. No increase over basal levels of the fluorescence of DMAV was observed. As a control, free cysteines or reduced DMAV produced a strong fluorescence signal (not shown). It is concluded that DMAV does not contain free cysteines that could mediate its antioxidant activity. To verify whether methionines in DMAV were oxidized, the protein was incubated with X/XO, and its mass was evaluated by MS. No change in mass compatible with methionine oxidation was observed (not shown).

**FIGURE 2.** DMAV inhibits collagen-induced platelet aggregation. A, human platelet-rich plasma ($2 \times 10^5$/μl) was incubated with DMAV for 1 min (concentrations are given for each trace) followed by the addition of different platelet agonists, as indicated. Platelet aggregation was estimated by turbidimetry under test tube-stirring conditions. Washed human platelets were employed when thrombin was used as an agonist. The traces represent a typical experiment. B, DMAV does not affect platelet adhesion to fibrillar or soluble collagen I immobilized in 96-well plates. Calcein-AM-labeled platelets were added to the wells and incubated for 1 h at 37 °C. Wells were washed with Tyrode-BSA. EDTA was used as a control. Fluorescence was detected with excitation at 485 nm and emission at 530 nm. Significance (*) was set at $p < 0.05$ (t test). C, DMAV does not interact with GPVI by SPR. GPVI was immobilized in a CMS sensor chip, and DMAV was used as an analyte. No increase in resonance was observed in the presence of DMAV (1 μM). Convulxin (10 nmol/liter), a GPVI ligand, was used as positive control. D, isothermal titration calorimetry for ADP or cTXA$_2$ interaction with DMAV. Top panels, base line-adjusted heats per injection of ADP (20 μmol/liter) or cTXA$_2$ (20 μmol/liter) into DMAV (2.0 μmol/liter). Bottom panels, molar enthalpies per injection for ADP or cTXA$_2$ interaction with DMAV. No binding was observed.
A Novel Family of Salivary Platelet Inhibitors

Next, DMAV was incubated with EDTA to chelate metals potentially bound to the protein. Fig. 4 shows that DMAV loses its antioxidant activity in the presence of EDTA (5 mmol/liter), which is consistent with a metal-dependent activity. In contrast, no inhibition of the antioxidant activity of Cu,Zn-SOD was detected, because it tightly interacts with Cu\(^{2+}\)/Zn\(^{2+}\) (42). The distinct sensitivity of DMAV and Cu,Zn-SOD for EDTA also implies that our preparation is devoid of contaminating E. coli Cu,Zn-SOD.

DMAV Binds Divalent Metal and ICP-MS Results—To estimate the metal content of recombinant DMAV, a highly purified sample was applied to ICP-MS, which is the most sensitive method available to evaluate metals and other ions present in a given sample (35). Fig. 5A presents the ratio (ion content in the sample, ng/g)/ion content in the buffer, ng/g) in the preparation. The results indicate that DMAV binds Co\(^{2+}\), Zn\(^{2+}\), and Cu\(^{2+}\). Additionally, Ni\(^{2+}\) was found in our sample (not shown), which is often a contaminant detected by ICP-MS. No other ion of the periodic table was found to interact with DMAV. Next, we evaluated whether DMAV binds additional metals provided in purified form. For these experiments, DMAV was incubated with EDTA and extensively dialyzed against HEPES-saline. Each metal (30 \mu mol/liter) was added to DMAV (10 \mu mol/liter), and after 30 min, the mixture was again extensively dialyzed. Fig. 5B demonstrates that DMAV equally binds Cu\(^{2+}\), Mn\(^{2+}\), Ni\(^{2+}\), Co\(^{2+}\), and Zn\(^{2+}\). When no metal was added to DMAV, only trace amounts of Zn\(^{2+}\) and Cu\(^{2+}\) were identified in the sample, indicating DMAV bound to trace metals present in the buffer. Next, the relative specificity of DMAV for Cu\(^{2+}\) and other metals was evaluated. In competition assays, DMAV was added to a mixture containing equal concentrations of Cu\(^{2+}\), Mn\(^{2+}\), Ni\(^{2+}\), Co\(^{2+}\), and Zn\(^{2+}\) followed by dialysis. Only Cu\(^{2+}\) was identified in the preparation (Fig. 5C). In displacement assays, DMAV was incubated with Mn\(^{2+}\), Ni\(^{2+}\), Co\(^{2+}\), and Zn\(^{2+}\), followed by the addition of Cu\(^{2+}\), and dialyzed. Fig. 5D demonstrates that only Cu\(^{2+}\) was found associated with DMAV.

Fluorescence Spectroscopy for DMAV—Tryptophan fluorescence spectra of metal-free and Cu\(^{2+}\)-complexed preparations of DMAV were employed to determine the relative affinity of the interaction identified by ICP-MS. The addition of CuSO\(_4\) induced quenching of the fluorescence to 30% of the initial intensity, suggesting that tryptophan indoles moved to a more hydrophobic environment (Fig. 6A). In contrast, no change in intrinsic fluorescence was observed when Li\(_2\)SO\(_4\) was added to DMAV (Fig. 6A, dotted lines). Data points were fitted by nonlinear regression to a single-site hyperbolic model, which resulted in an apparent K_D of 20.7 \mu mol/liter (Fig. 6B). This value does not reflect the true affinity of DMAV for the ion because it varies with the concentration of DMAV used in the assay (20 \mu mol/liter). As an additional control, no change in the intrinsic fluorescence spectroscopy was observed when CuSO\(_4\) (60 \mu mol/liter) was added to DM146 (gi315270899), another E. coli expressed salivary protein from D. maxima (Fig. 6C). The UV spectrum of DMAV was performed, and peak absorbance was detected at 280 nm. Additional peaks were not observed at longer wavelengths in the presence of Cu\(^{2+}\) (data not shown), in contrast to Cu\(^{2+}\) oxidases (so-called “blue copper proteins”) (43, 44).

Comparison of the Antioxidant Activities of Cu\(^{2+}\)-DMAV and Cu,Zn-SOD—To verify the antioxidant potential of the protein, DMAV (10 \mu mol/liter) previously incubated with (20 \mu mol/liter) Cu\(^{2+}\) was extensively dialyzed against PBS, pH 7.4.
FIGURE 4. DMAV is an antioxidant that scavenges O$_2^-$. A, neutrophils were activated with PMA (5 nmol/liter) in the presence of increasing concentrations of DMAV. Superoxide was detected using Diogenes luminescent reagent for O$_2^-$. B, neutrophils were activated as in A, but O$_2^-$ was detected with Lucigenin (20 μmol/liter). C, O$_2^-$ was generated by an X/XO system; luminescence was detected using luminol (500 μmol/liter). D, several proteins (DM146, ixolaris, triplatin, 9.3 kDa, SVEP, and yellow protein; 2 μmol/liter) were expressed and purified as DMAV and tested side by side. Detection of O$_2^-$ was performed with Luminol (500 μmol/liter). E, O$_2^-$ generation was detected using a Clark electrode at 550 nm. F, DMAV (5 μmol/liter) does not affect the enzymatic function of X/XO, determined by uric acid production at 293 nm. G, effects of DMAV on generation of H$_2$O$_2$, X (500 μmol/liter)/XO (6.3 milliunits/ml) was used to generate H$_2$O$_2$, which was detected with the Amplex Red reagent. In control, spontaneous dismutation of O$_2^-$ is observed, which is increased in the presence of Cu,Zn-SOD (4 milliunits/ml). DMAV (5 μmol/liter) did not increase H$_2$O$_2$ production. H, DMAV does not display catalase activity. Different concentrations of H$_2$O$_2$ were incubated for 15 min with PBS or DMAV (2 μmol/liter) and detected with Amplex Red reagent as described under “Experimental Procedures.” I, catalase activity. XO (0.7 milliunits/ml) was added to a solution containing hypoxanthine (500 μmol/liter), and O$_2$ consumption was detected with a Clark electrode. After 15 min, catalase (333 units/ml) was added to the chamber, and a peak of O$_2$ is observed. No effects were observed after the addition of DMAV (0.5 μmol/liter). J, DMAV displays metal-dependent antioxidant activity. DMAV (5 μmol/liter) or Cu,Zn-SOD (0.42 unit/ml) was incubated with EDTA (5 mmol/liter) for 15 min and tested in the cytochrome c reduction assay. Antioxidant activity of DMAV was abolished by EDTA (n = 3). Significance (*) was set at p < 0.05 (analysis of variance). A.U., arbitrary units. Error bars, S.E.
To study the kinetics of the reaction of Cu$^{2+}$/H$^+$-DMAV with O$_2$ generated by X/XO, the rate of formation of cyt c reduction was spectrophotometrically monitored at pH 7.8 in the absence (V) and presence (v) of various Cu$^{2+}$/H$^+$-DMAV concentrations. Results obtained by this method compare well with direct measurement of O$_2$ estimated by pulse radiolysis (45). Fig. 7, A and B, show the progress curves of cyt c reduction with increasing concentrations of Cu$^{2+}$/DMAV or Cu,Zn-SOD respectively.

Fig. 7, C and D, shows the dose-response curves for the results presented in 7, A and B, respectively, with a calculated IC$_{50}$ of ~50 nmol/liter for Cu$^{2+}$/DMAV and 1 nM for Cu,Zn-SOD.
FIGURE 7. Comparison of the antioxidant activity of Cu2+-DMAV and Cu,Zn-SOD. Cytochrome c reduction assays were performed by the addition of XO (1.2 units/ml) to hypoxanthine (0.5 mM) in phosphate buffer, pH 7.8, in the presence of Cu2+-DMAV (A) 0 nM (a), 25 nM (b), 50 nM (c), 100 nM (d), 250 nM (e), 375 nM (f), or 500 nM (g)) or Cu,Zn-SOD (B) 0 nM (a), 0.4 nM (b), 0.8 nM (c), 1.6 nM (d), 3.2 nM (e), 6.5 nM (f), and 13 nM (g)). Progress curves are shown. Transformation of the data in A and B is shown as a function of $V_{\text{max}}$, and [Cu2+-DMAV] (nM) (C) or [Cu,Zn-SOD] (nM) (D), respectively. Transformation of the data in C and D is shown as a function of $V_{\text{max}}$ and [Cu2+-DMAV] (nM) (E) or [Cu,Zn-SOD] (nM) (F), $V$, initial velocity; $v$, final velocity. The linear transformation of the data suggests a catalytic process (34).

SOD. Data were analyzed by plotting $V/v$ as a function of [Cu2+-DMAV] according to Krishna et al. (33) (Fig. 7E). Fig. 7F shows the same transformation for Cu,Zn-SOD. From the slope of the line and knowing $K_{\text{M}}$, superoxide (33, 46) at pH 7, the $k_{\text{app}}$ for the Cu2+-DMAV interaction with O2− was calculated to be $3.1 \times 10^6$ mol liter−1 s−1. This is ~30–50 times less than the $K_{\text{cat}}$ (2–3 $\times$ 107 mol liter−1 s−1) observed for [Cu,Zn-SOD] (33, 39, 45–47). The antioxidant activity of Cu2+-DMAV was not affected by the presence of catalase in the assay (not shown). McCord and Fridovich (48) defined the specific activity of SOD in units/mg, where 1 unit is the amount in mg of protein that inhibits 50% of the reduction of 10 μmol/liter cytochrome c by O2− (generated by the X/O system) in a 3.0-ml reaction volume containing 50 mmol/liter phosphate buffer at pH 7.8. This is ~430 units/mg Cu2+-DMAV. DMAV was devoid of antioxidant activity when preincubated with Zn2+ (data not shown).

DMAV Binds to Heparin and Sulfated Glycosaminoglycans—It has been reported that extracellular SOD interacts with heparin through its C terminus (49). To verify whether DMAV interacts with sulfated glycosaminoglycans, it was immobilized in a CMS sensor chip, followed by injection of sulfated glycosaminoglycans. Fig. 8A shows that DS50K and DS500K avidly interact with DMAV. Binding was also detectable with heparin and heparan sulfate. In contrast, no signal was observed when non-sulfated dextran 12K, non-sulfated dextran 670K, chondroitin sulfate, or enoxaparin were used as analytes (not shown). Next, the kinetics of DMAV interaction with DS500K and DS50K were studied. Sensorgrams are shown in Fig. 8, B and C, and data were fitted with a bivalent analyte model. In both cases, the association phase was followed by a very slow dissociation rate, which does not allow precise calculation of the $k_{\text{off}}$. In these cases, the $K_f$ can be determined by steady-state kinetics. Fig. 8D shows that DS500K and DS50K interact with immobilized DMAV in a saturable manner with a $K_f$ of ~0.41 nmol/liter ± 0.05 nmol/liter and 1.96 nmol/liter ± 0.2 nmol/liter, respectively. Fig. 8, E and F, also demonstrates that DMAV interacts with heparin sulfates or heparin, respectively. To estimate the $K_f$ of heparin-DMAV interactions with accuracy, biotinylated heparin was coupled to neutravidin immobilized in a CM5 chip, and DMAV was used as an analyte. Sensorgrams are depicted in Fig. 8G. The inset presents the fit of the data using steady-state kinetics, which resulted in a $K_f$ of 97.0 ± 4.5 nmol/liter. The interaction of DMAV with heparin was also tested using a heparin-agarose column. Fig. 8H demonstrates that elution of DMAV was observed at ~1 mol/liter NaCl. This result provides additional evidence to conclude that DMAV is a heparin-binding protein. In order to evaluate whether DMAV binds to membranes, it was incubated with PC/PS or activated platelets as described under “Experimental Procedures.” In both cases, no interaction was observed (not shown), excluding DMAV as a phospholipid-binding protein.

Antioxidant Activity Is Present in the SG of D. maxima—To examine whether the SG of D. maxima exhibits antioxidant activity, salivary gland homogenate (SGH) was prepared, and the supernatant was obtained after centrifugation. Fig. 9A shows that SGH inhibits the signal of O2− generated by X/OX with an IC50 of ~0.05 pairs/assay. In addition, SGH dose-dependently attenuated collagen (0.53 μg/ml)-induced platelet aggregation (Fig. 9B).

Because SGH is a complex mixture of proteins, and different molecules may exhibit antioxidant activity or inhibit platelet aggregation, our goal was to verify whether specific fraction-containing DMAV also exhibited the activities. SGH was prepared from 100 pairs of glands and supernatant loaded into a G-75 gel filtration column. Fig. 9C shows the elution profile of the homogenate, which was characterized by a large peak where most lipocalins (the most abundant protein family in triatomine saliva) are found. Recombinant DMAV loaded onto the column eluted at 11.5–12.5 min, which is compatible with its molar mass of 25 kDa (Fig. 9D). To determine the elution profile of native DMAV, an aliquot of each fraction was used to immobilize the protein, and an ELISA was performed using polyclonal antibody as a probe. Fig. 9E shows that the peak of DMAV recognized by the antibodies coincides with the elution pattern of recombinant protein. To confirm the presence of DMAV in the SGH, fractions 21 and 23, which flank the maximum antibody titers indicative of DMAV by ELISA, were chosen. These fractions were loaded into a one-dimen-
professional SDS-PAGE followed by gel-tryptic digestion and MS/MS of the bands. Fig. 9, F (for fraction 21) and G (for fraction 23), shows that DMAV was identified without ambiguity as one of the most abundant components in addition to lipocalins. Fractions 21 and 23 were also evaluated for the Cu²⁺ content by ICP-MS. Fig. 9H demonstrates that Cu²⁺ is...
detectable in fraction 21, and higher levels are observed in fraction 23. Finally, fractions 21 and 23 exhibit antioxidant activity using the cyt c reduction assay, which was metal-dependent because it was blocked by EDTA (Fig. 9f).

**DISCUSSION**

Studying the function of the antigen-5 family of proteins revealed that members of this family exhibit antioxidant activity. This was concluded based on several enzymatic or cell-
based assays. Accordingly, recombinant DMAV was found to scavenge $O_2^-$ produced by neutrophil activated by PMA and detected by two chemically unrelated luminescence reagents that react with $O_2^-$ (e.g. Diogenes reagent and lucigenin). DMAV also inhibits luminescence generated by luminol or the reduction of cyt c by $O_2^-$ generated in the X/XO system. Because DMAV does not block uric acid activity or consumption of oxygen after the addition of X/XO, it was evident that this molecule exhibits direct antioxidant properties through removal of $O_2^-$. In addition, the antioxidant activity of DMAV is specific for this molecule, because it was not found for several other salivary proteins expressed in *E. coli* or in insect cells.

Control experiments excluded the possibility that free thiols (41) or methionine oxidation (40) mediates the antioxidant function of DMAV. In contrast, EDTA completely abolished its antioxidant function, indicating a metal-dependent mechanism. ICP-MS was used to determine the metal content in DMAV. Results revealed that DMAV binds divalent ions Mn$^{2+}$, Co$^{2+}$, Ni$^{2+}$, Cu$^{2+}$, and Zn$^{2+}$. Through competition and displacement studies, it was concluded that DMAV has higher specificity for Cu$^{2+}$ over other metals. Moreover, the addition of Cu$^{2+}$ to apo-DMAV decreased the intrinsic fluorescence of the protein, indicating a conformational change upon binding. This experiment estimated an apparent $K_d$ in the micromolar range, which is an overestimation because it is of the same order of magnitude as the protein concentration used in the assay. Under identical experimental conditions, Li$_2$SO$_4$ did not induce protein intrinsic fluorescence change. Furthermore, CuSO$_4$ does not induce intrinsic fluorescence change in DM146, an unrelated recombinant salivary protein.

Kinetic studies using a cytochrome c reduction assay suggest that Cu$^{2+}$-DMAV operates as a catalyst and not as a simple scavenger of $O_2^-$ (33, 45). Our interpretation is that antigen-5 members belong to a novel family of metal-dependent antioxidant enzymes. Of note, identification of Cu$^{2+}$ as a ligand for DMAV is congruent with the identification of metal (i.e. Zn$^{2+}$) coordination in the structure of antigen-5 members from hookworm and snake venoms (50, 51). However, it remains to be determined how DMAV interacts with Cu$^{2+}$ and the mechanism of metalation. The finding that Cu$^{2+}$ preferentially binds to DMAV is also particularly relevant because Zn$^{2+}$ does not exhibit redox potential and therefore cannot confer antioxidant properties to a protein. Structural information will be critical to gain further insight on the mechanism of action of DMAV.

With respect to metal requirements for antioxidant activity, Cu$^{2+}$-DMAV resembles Cu,Zn-SOD, which binds Cu$^{2+}$ and also exhibits one of the highest $k_{cat}$ values ($k_{cat}$ for $O_2^-$, $2-3 \times 10^8$ mol liter$^{-1}$ s$^{-1}$) (39, 45, 47). It has also been shown that several Cu$^{2+}$ salts or low molar mass Cu$^{2+}$ chelates exhibit a high catalytic redox potential and scavenge $O_2^-$ with efficiency close to that of Cu,Zn-SOD (52–55). Cu$^{2+}$-binding proteins, such as ceruloplasmin (56), prion protein PrP (57), and HAH1 (58), also display antioxidant activity. It is conceivable that DMAV employs an extremely efficient antioxidant mechanism for removal of $O_2^-$ that takes advantage of the high catalytic redox potential of Cu$^{2+}$ ($K_{cat}$ for $O_2^-$, 0.2–2 $\times 10^9$ mol liter$^{-1}$ s$^{-1}$), which is 1000 times higher than that for Mn$^{2+}$ ($K_{cat}$ for $O_2^-$, 1.3–8.9 $\times 10^6$ mol liter$^{-1}$ s$^{-1}$) (59, 60). It is important to recognize that Cu$^{2+}$ binding molecules do not always behave as antioxidants. For example, Cu$^{2+}$-bound amyloid $\beta$ peptide from Alzheimer disease (61) and $\alpha$-synuclein-Cu$^{2+}$ (62), or hydroquinone-Cu$^{2+}$ complexes (63) are considered pro-oxidents, because they promote H$_2$O$_2$ formation without scavenging $O_2^-$. Accordingly, the pro- or antioxidant activity of Cu$^{2+}$ in a protein complex is dependent on the number of Cu$^{2+}$ per molecule, the redox state of Cu$^{2+}$, and the specific residues that coordinate the interaction with the metal (64–66).

Cu,Zn-SOD and Cu$^{2+}$-DMAV differ in several respects. On a molar basis, Cu$^{2+}$-DMAV is about 30–50 times less active than Cu,Zn-SOD. EDTA abolishes the antioxidant activity of Cu$^{2+}$-DMAV and other complexes (52, 53), but not Cu,Zn-SOD. This indicates that the interaction of DMAV with Cu$^{2+}$ is not tight as observed with Cu,Zn-SOD (42, 45), as confirmed experimentally (Fig. 68). Moreover, we did not detect accumulation of H$_2$O$_2$ production in the presence of DMAV. It is concluded that the products of spontaneous dismutation are identical to the products of the DMAV-catalyzed reaction, as initially reported for Cu,Zn-SOD (48). Furthermore, the Cu$^{2+}$-binding proteins such as tyrosinase, laccase, ascorbate oxidase (66), and, most notably, ceruloplasmin, scavenge O$_2^-$ but do not produce H$_2$O$_2$ (56, 67). It has been suggested that dismutation of $O_2^-$ by these proteins occurs through mechanisms that result in the production of water instead of H$_2$O$_2$ (66), although the chemistry of such dismutation is not completely understood (64–66). It is possible that DMAV might operate in a similar fashion.

Functionally, the antioxidant activity of DMAV or TIAV, which was characterized here as scavenging of $O_2^-$ in vitro, is consistent with inhibition of low doses of collagen-induced platelet aggregation, ATP secretion, and TXA$_2$ production. Indeed, Krotz et al. (10) and Caccese et al. (11) found that collagen, but not ADP or thrombin, is the only agonist that increases O$_2^-$ extracellularly. O$_2^-$ released by platelets also mediates platelet recruitment, by a mechanism inhibited by Cu,Zn-SOD (10). Furthermore, extracellular antioxidant N-acetylcysteine inhibits aggregation by low doses of collagen only and

**FIGURE 9.** Dipetalogaster maxima salivary gland; effects on platelets, antioxidant activity, and Cu$^{2+}$ content. A, O$_2^-$ was generated by the X (500 $\mu$mol/liter)/XO (1.2 milliliters/ml) in the presence of SGH of *D. maxima*. Superoxide was detected by chemiluminescence using luminol. B, effects on platelet aggregation. Platelets were incubated with the SGH of *D. maxima* followed by the addition of collagen (0.53 $\mu$g/ml). Aggregation was detected by turbidimetry in a Lumi-Aggregometer. C, fractionation of the SG of *D. maxima*. SGH corresponding to 100 pairs of *D. maxima* was applied to a Sephadex-G75 column as specified in Materials and Methods.
suppresses production of TXA₂ (12). In support of our findings that DMAV inhibits extracellular O₂⁻ is the result presented in Fig. 3B showing that Cu,Zn-SOD inhibits platelet aggregation by low doses of collagen only, but, as reported before, it does not interfere with aggregation induced by high concentrations, such as 6 µg/ml (10). Furthermore, the increase in extracellular O₂⁻ levels occurs after 2 min of collagen addition and coincides with the appearance of large aggregates (8). Our results demonstrated that the anti-aggregatory effect of DMAV is only observable at later time points (no effects in shape change), when the production of O₂⁻ has already started. Also, thrombus formation under flow in a collagen surface is only partially attenuated by negative modulators of intracellular O₂⁻ production, such as NADPH oxidase inhibitors (e.g. diphenylene iodonium, apocynin, and 2-acetylcyclohexathiazine) or Cu,Zn-SOD mimetic (e.g. MnTMPyP) (38, 68). In agreement with these results, TIAV, which acts extracellularly, marginally affected thrombus formation in vitro (Fig. 3F).

It is important to emphasize that although convulxin (Cvx) generates intracellular ROS (24, 69), it does not promote ROS increase extracellularly; nor does Cu,Zn-SOD inhibit platelet activation by Cvx (69). These results are therefore in agreement with the lack of effects of DMAV in aggregation caused by low doses of Cvx (Fig. 2A). Actually, this result is not surprising, because Cvx is a strong agonist that promotes direct PLCγ2 activation and that relies only marginally on secondary mediators (e.g. TXA₂ and ADP) to induce full platelet aggregation (70–72). Although thrombin or thrombin-receptor activating peptide (TRAP) induce ROS production intracellularly (38, 69) and aggregation is negatively modulated by intracellular antioxidants MnTMPyP (20) or Tempol (73), extracellular O₂⁻ in the supernatant of thrombin-activated platelets has not been detected by Krotz et al. (10) or Caccese et al. (11). Plausibly, this explains why DMAV does not affect thrombin-induced platelet aggregation (Fig. 2A). Finally, our experiments using ITC and platelet aggregation assays excluded the possibility that pro-aggregatory molecules involved in platelet aggregation by collagen, such as ADP or TXA₂, PGG₂/PGD₂, and 12-HETE (37), are targets for DMAV. It is concluded that DMAV interrupts platelet aggregation by a mechanism never reported before for a salivary protein that is explained by scavenging O₂⁻. DMAV also attenuates the O₂⁻ signal generated by PMA-activated neutrophils, validating the view that different sources of ROS production are effectively blocked by the inhibitor.

Removal of O₂⁻ is particularly important because it is the limiting step in the generation of other ROS (e.g. hydroxyl and peroxyl). Although several reports have demonstrated a pivotal role for intracellular O₂⁻ as a signaling molecule and inflammatory mediator (74–77), extracellularly O₂⁻ also plays an important role in inflammation, as evidenced by the inhibitory role of extracellular SOD (EC-SOD or SOD3) in neutrophil inflammation in the lung and in the skin (78–83). Conceivably, DMAV interferes with the proinflammatory effects of extracellular ROS produced by neutrophils, platelets, and other cell types (84, 85), resulting in attenuation of expression of procoagulant tissue factor, NET formation, cytokine release, lipid peroxidation, and conversion of nitric oxide to peroxynitrite in the vasculature (86–90). In other words, scavenging of extracellular O₂⁻ down-modulates a myriad of proinflammatory reactions.

SPR results and affinity chromatography experiments demonstrated that DMAV interacts with immobilized heparin (K_D ~100 nmol/liter) and other sulfated compounds (e.g. heparan sulfate and dextran sulfate). This finding reveals a remarkable similarity of DMAV with extracellular Cu,Zn-SOD, which binds heparin sulfate proteoglycans on cell surfaces via its heparin-binding domain (86). It is conceivable that binding of DMAV to endothelial cells increases the effective concentration of the enzyme and the antioxidant tonus at bite sites. Further, the presence of DMAV in the salivary gland was supported by the identification of metal-dependent antioxidant activity in chromatographic fractions containing native DMAV, confirmed by mass spectrometry and ELISA. Nevertheless, purification of native DMAV from the gland will be necessary in order to fully characterize it as an enzyme in nature, through the determination of the metal content and the kinetics and products of the reaction with O₂⁻. Finally, it is notable that the salivary glands of blood-sucking arthropods reportedly contain at least one antplatelet, one anticoagulant, and one vasodilator (1). Based on the results presented herein, and because antigen-5 members are ubiquitously found and relatively abundant, it is fair to say that at least one antioxidant might also be present in these glands.

The discovery of novel protein families in insect salivary protein or other exogenous secretions has proven particularly important in our understanding of vertebrate vascular biology and in providing tools for biochemistry and cell biology or to predict the function of endogenous proteins (1, 2). By analogy with DMAV, we speculate that other endogenous CAP/antigen-5 members (e.g. GLIPR1, GAPRI, PL15, and CRISP) (26) might also behave as metal-binding proteins with pro- or anti-oxidant functions. In conclusion, expression of antigen-5 members in the SGs of insects and ticks counteracts the diverse proinflammatory function of O₂⁻ in the microcirculation, contributing to the successful feeding of blood-sucking arthropods.

Acknowledgments—We are thankful to Ming Zheng, Renee Olano, and Carl Hammer (NIAID, National Institutes of Health, Research Technology Branch) for mass spectrometry analysis. We thank Dr. Murali Krishna (NCI/NIH) for discussions and expertise with the Clark electrode. We are grateful to Brenda Rae Marshall (Division of Intramural Research Program Support Staff, NIAID, National Institutes of Health) for editing.

REFERENCES

1. Ribeiro, J. M., and Francischetti, I. M. (2003) Role of arthropod saliva in blood feeding. Sialome and post-sialome perspectives. Annu. Rev. Entomol. 48, 73–88
2. Francischetti, I. M. (2010) Platelet aggregation inhibitors from hematophagous animals. Toxicon 56, 1130–1144
3. Mans, B. J., Francischetti, I. M. (2010) Sialomic perspectives on the evolution of blood-feeding behavior in arthropods. Future therapeutics by natural design. Toxins and Hemostasis: From bench to Bedside (Kini, R. M., Cleemston, K. J., Markland, F. S., McLane, M. A., and Morita, T., eds) pp.
21. Clemetson, K. J., and Clemetson, J. M. (2007) Collagen receptors as potential targets for novel anti-platelet agents. *Curr. Pharm. Des.* 13, 2673–2683

22. Begonja, A. J., Teichmann, L., Geiger, J., Gambaryan, S., and Walter, U. (2006) Platelet regulation by NO/cGMP signaling and NAD(P)H oxidase-generated ROS. *Blood Cells Mol. Dis.* 36, 166–170

23. Watson, S. P. (2009) Platelet activation by extracellular matrix proteins in haemostasis and thrombosis. *Curr. Pharm. Des.* 15, 1358–1372

24. Arthur, J. F., Qiao, J., Shen, Y., Davis, A. K., Dunne, E., Berndt, M. C., Gardiner, E. E., and Andrews, R. K. (2012) ITAM receptor-mediated generation of reactive oxygen species in human platelets occurs via Syk-dependent and Syk-independent pathways. *J. Thromb. Haemost.* 10, 1133–1141

25. Hubbard, G. P., Wolfram, S., Lovegrove, J. A., and Gibbins, J. M. (2004) Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. *J. Thromb. Haemost.* 2, 2138–2145

26. Gibbs, G. M., Roelants, K., and O’Bryan, M. K. (2008) The CAP superfamily. Cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins. Roles in reproduction, cancer, and immune defense. *Endocr. Rev.* 29, 865–897

27. Francischetti, I. M., Saliou, B., Leduc, M., Carlini, C. R., Hatmi, M., Randon, J., Falli, A., and Bon, C. (1997) Convulxin, a potent platelet-aggregating protein from *Crotalus durissus terrificus* venoms, specifically binds to platelets. *Toxicol. Sci.* 35, 1217–1228

28. Jandot-Perrus, M., Busfield, S., Lagrue, A. H., Xiong, N., Debili, N., Chickering, T., Le Couedic, J. P., Goodacre, R., Dussault, B., Fraser, C., Vainchenker, W., and Villeval, J. L. (2000) Cloning, characterization, and functional studies of human and mouse glycoprotein VI. A platelet-specific collagen receptor from the immunoglobulin superfamily. *Blood* 96, 1798–1807

29. Francischetti, I. M., Assumpção, T. C., Ma, D., Li, Y., Vance, E. C., Uieda, W., and Ribeiro, J. M. (2013) The “Vampirome”: transcriptome and proteome analysis of the principal and accessory submaxillary glands of the vampire bat *Desmodus rotundus*, a vector of human rabies. *J. Proteomics* 82, 288–319

30. Assumpção, T. C., Alvarenga, P. H., Ribeiro, J. M., Andersen, J. F., and Francischetti, I. M. (2010) Dipetidolipid, a novel multifunctional salivary lipocalin that inhibits platelet aggregation, vasoconstriction, and angiogenesis through unique binding specificity for TxA2, PGF2α, and 15(S)-HETE. *J. Biol. Chem.* 285, 39000–39012

31. Whitmore, J., and Wallace, B. A. (2004) DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. *Nucleic Acids Res.* 32, W668–W673

32. Whitmore, L., and Wallace, B. A. (2008) Protein secondary structure analyses from circular dichroism spectroscopy. Methods and reference databases. *Biopolymers* 89, 392–400

33. Krishna, M. C., Russo, A., Mitchell, J. B., Goldstein, S., Dafni, H., and Samuni, A. (1996) Do nitroxide antioxidants act as scavengers of O2·− or as SOD mimics? *J. Biol. Chem.* 271, 26026–26031

34. Krishna, M. C., Samuni, A., Taira, J., Goldstein, S., Mitchell, J. B., and Russo, A. (1996) Stimulation by nitroxides of catalase-like activity of hemeproteins. Kinetics and mechanism. *J. Biol. Chem.* 271, 26018–26025

35. Schultz, M. K., Biegalski, S. R., Inn, K. G., Yu, L., Burnett, W. C., Thomas, J. L., and Smith, G. E. (1999) Optimizing the removal of carbon phases in soils and sediments for sequential chemical extractions by coulometry. *J. Environ. Monit.* 1, 183–190

36. Collin, N., Assumpção, T. C., Mizurini, D. M., Gilmore, D. C., Dutra-Oliveira, A., Kotsyfakis, M., Sá-Nunes, A., Teixeira, C., Ribeiro, J. M., Monteiro, R. Q., Valenzuela, J. G., and Francischetti, I. M. (2012) Lufaxin, a novel factor-Xa inhibitor from the salivary gland of the sand fly *Lutzomyia longipalpis* blocks protease-activated receptor 2 activation and inhibits inflammation and thrombosis in vivo. *Arterioscler. Thromb. Vasc. Biol.* 32, 2185–2198

37. Watson, S. P., Auger, J. M., McCarty, O. J., and Pearce, A. C. (2005) GPVI and integrin αIIb β3 signaling in platelets. *J. Thromb. Haemost.* 3, 1752–1762

38. Begonja, A. J., Gambaryan, S., Geiger, J., Aktas, B., Pozgajova, M., Nieswandt, B., and Walter, U. (2005) Platelet NAD(P)H-oxidase-generated ROS production regulates αIIbβ3-integrin activation independent of the NO/cGMP pathway. *Blood* 106, 2757–2760

39. Fridovich, I. (1995) Superoxide radical and superoxide dismutases. *Annu.*
A Novel Family of Salivary Platelet Inhibitors

Rev. Biochem. 64, 97–112
Levine, R. L., Mosoni, L., Berlett, B. S., and Stadtmann, E. R. (1996) Methionine residues as endogenous antioxidants in proteins. Proc. Natl. Acad. Sci. U.S.A. 93, 15036–15040

1. Cox, A. G., Winterbourn, C. C., and Hampton, M. B. (2010) Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. Biochem. J. 425, 313–325

2. Goto, J. J., Zhu, H., Sanchez, R. J., Nersissian, A., Gralla, E. B., Valentine, J. S., and Cabelli, D. E. (2000) Loss of in vitro metal ion binding specificity in mutant copper-zinc superoxide dismutases associated with familial amyotrophic lateral sclerosis. J. Biol. Chem. 275, 1007–1014

3. Kosman, D. J. (2010) Multicopper oxidases. A workshop on copper coordination chemistry, electron transfer, and metallophysiology. J. Biol. Inorg. Chem. 15, 15–28

4. Sakurai, T., and Kataoka, K. (2007) Structure and function of type I copper in multicopper oxidases. Cell Mol. Life Sci. 64, 2642–2656

5. Goldstein, S., Fridovich, I., and Czapski, G. (2006) Kinetic properties of Cu,Zn-superoxide dismutase as a function of metal content. Order restored. Free Radic. Biol. Med. 41, 937–941

6. Butler, J., Koppenol, W. H., and Margoliash, E. (1982) Kinetics and mechanism of the reduction of ferricytochrome c by the superoxide anion. J. Biol. Chem. 257, 10747–10750

7. Klug, D., Rabani, J., and Fridovich, I. (1972) A direct demonstration of the catalytic action of superoxide dismutase through the use of pulse radiolysis. J. Biol. Chem. 247, 4839–4842

8. McCord, J. M., and Fridovich, I. (1969) Superoxide dismutase. An enzymic function for erythrocyte peroxidase (hemoperoxidase). J. Biol. Chem. 244, 6049–6055

9. Sandström, J., Carlsson, L., Marklund, S. L., and Edlund, T. (1992) The heparin-binding domain of extracellular superoxide dismutase C and formation of variants with reduced heparin affinity. J. Biol. Chem. 267, 18205–18209

10. Asojo, O. A. (2011) Structure of a two-CAP-domain protein from the human hookworm parasite Necator americanus. Acta Crystallogr. D Biol. Crystallogr. 67, 455–462

11. Wang, Y. L., Kuo, J. H., Lee, S. C., Liu, J. S., Hsieh, Y. C., Shih, Y. T., Chen, C. J., Chiu, J. J., and Wu, W. G. (2010) Cobra CRISP functions as an inflammatory modulator via a novel Zn²⁺- and heparan sulfate-dependent transcriptional regulation of endothelial cell adhesion molecules. J. Biol. Chem. 285, 37872–37883

12. Kubota, S., and Yang, J. T. (1984) Bicyclo(histidylyhistidine) copper(II) complex that mimics the active center of superoxide dismutase has its catalytic activity. Proc. Natl. Acad. Sci. U.S.A. 81, 3283–3286

13. Weser, U., and Schubotz, L. M. (1981) Catalytic reaction of copper complexes with superoxide. Agents Actions Suppl. 8, 103–120

14. Brigelius, R., Spöttel, R., Bors, W., Lengfelder, E., Saran, M., and Weser, U. (1974) Superoxide dismutase activity of low molecular weight Cu2 plus-chelates studied by pulse radiolysis. FEBS Lett. 72, 77–72

15. Fielden, E. M., Roberts, P. B., Bray, R. C., Lowe, D. J., Mautner, G. N., Rotilio, G., and Calabrese, L. (1974) Mechanism of action of superoxide dismutase from pulse radiolysis and electron paramagnetic resonance. Evidence that only half the active sites function in catalysis. Biochim. Biophys. Acta 139, 49–60

16. Goldstein, I. M., Kaplan, H. B., Edelson, H. S., and Weissmann, G. (1979) Ceruloplasmin. A scavenger of superoxide anion radicals. J. Biol. Chem. 254, 4040–4045

17. Davies, P., and Brown, D. R. (2008) The chemistry of copper employing the Mn(III)/Mn(IV) redox couple. Inorg. Chem. 47, 726–739

18. Huang, X., Atwood, C. S., Hartshorn, M. A., Multhaup, G., Goldstein, L. E., Scarp, R. C., Cuajiangco, M. P., Gray, D. N., Lim, I., Moir, R. D., Tanzi, R. E., and Bush, A. I. (1999) The Aβ peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 7609–7616

19. Davies, P., Wang, X., Sarell, C. J., Drevett, A., Marken, F., Viles, J. H., and Brown, D. R. (2011) The syneclins are a family of redox-active copper binding proteins. Biochemistry 50, 37–47

20. Li, Y., Kuppusamy, P., Zweier, J. L., and Trush, M. A. (1995) ESR evidence for the generation of reactive oxygen species from the copper-mediated oxidation of the benzene metabolite, hydroquinone. Role in DNA damage. Chem. Biol. Interact. 94, 101–120

21. Bento, I., Silva, C. S., Chen, Z., Martins, L. O., Lindley, P. F., and Soares, C. M. (2010) Mechanisms underlying dioxygen reduction in laccases. Structural and modelling studies focusing on proton transfer. BMC Struct. Biol. 10, 28

22. Gardner, R., Salvador, A., and Moradas-Ferreira, P. (2002) Why does SOD overexpression sometimes enhance, sometimes decrease, hydrogen peroxide production? A minimalist explanation. Free Radic. Biol. Med. 32, 1351–1357

23. Frieden, E., Osaki, S., and Kobayashi, H. (1965) Copper proteins and oxygen. Correlations between structure and function of the copper oxidases. J. Gen. Physiol. 49, (suppl.) 213–252

24. Marklund, S. L. (1986) Ceruloplasmin, extracellular-superoxide dismutase, and scavenging of superoxide anion radicals. J. Free Radic. Biol. Med. 2, 255–260

25. Vargaftig, B. B., Prado-Franceschi, J., Chignard, M., Lefort, J., and Marlas, C. M. (2010) Regulation ofendothelial function by mitochondrial reactive oxygen species regulates platelet activation. Free Radic. Biol. Med. 45, 158–166

26. Faili, A., Randon, J., Francisciotti, I. M., Vargaftig, B. B., and Hatmi, M. (1994) Convulxin-induced platelet aggregation is accompanied by a powerful activation of the phospholipase C pathway. Biochem. J. 298, 87–91

27. Francischetti, I. M., Ghazaleh, F. A., Reis, R. A., Carlini, C. R., and Guimarães, J. A. (1998) Convulxin induces platelet activation by a tyrosine-kinase-dependent pathway and stimulates tyrosine phosphorylation of platelet proteins, including PLCγ2, independently of integrin αIIbβ3. Arch. Biochem. Biophys. 353, 239–250

28. Vargaftig, B. B., Prado-Franceschi, J., Chignard, M., Lefort, J., and Marlas, G. (1980) Activation of guinea-pig platelets induced by convulxin, a substance extracted from the venom of Crotalus durissus cascavella. Eur. J. Pharmacol. 68, 451–464

29. Clutton, P., Miernont, A., and Freedman, J. E. (2004) Regulation of endogenous reactive oxygen species in platelets can reverse aggregation. Arterioscler. Thromb. Vasc. Biol. 24, 187–192

30. Widlansky, M. E., and Gutterman, D. D. (2011) Regulation of endothelial function by mitochondrial reactive oxygen species. Antioxid. Redox Signal. 15, 1517–1530

31. Murphy, E., and Steenbergen, C. (2008) Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev. 88, 581–609

32. Leonarduzzi, G., Sottero, B., Testa, G., Biasi, F., and Poli, G. (2011) New insights into redox-modulated cell signalling. Curr. Pharm. Des. 17, 3994–4006

33. Thomas, S. R., Witting, P. K., and Drummond, G. R. (2008) Redox control of endothelial function and dysfunction. Molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 10, 1713–1765

34. Yasui, K., and Baba, A. (2006) Therapeutic potential of superoxide dismutase (SOD) for resolution of inflammation. Inflamm. Res. 55, 359–363

35. Ueda, J., Starr, M. E., Takahashi, H., Du, J., Chang, L. Y., Crapo, J. D., Evers, B. M., and Saito, H. (2008) Decreased pulmonary extracellular superoxide dismutase. Structural and modelling studies focusing on proton transfer. BMC Struct. Biol. 10, 28

36. Hassett, P., Curley, G. F., Contreras, M., Masteron, C., Higgins, B. D., O’Brien, T., Devaney, J., O’Toole, D., and Laffey, J. G. (2011) Overex-
pression of pulmonary extracellular superoxide dismutase attenuates endotoxin-induced acute lung injury. *Intensive Care Med.* **37**, 1680–1687
81. Gao, F., Koenitzer, J. R., Tobolewski, J. M., Jiang, D., Liang, J., Noble, P. W., and Oury, T. D. (2008) Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan. *J. Biol. Chem.* **283**, 6058–6066
82. Bowler, R. P., Nicks, M., Tran, K., Tanner, G., Chang, L. Y., Young, S. K., and Worthen, G. S. (2004) Extracellular superoxide dismutase attenuates lipopolysaccharide-induced neutrophilic inflammation. *Am. J. Respir. Cell Mol. Biol.* **31**, 432–439
83. Lee, Y. S., Cheon, I. S., Kim, B. H., Kwon, M. J., Lee, H. W., and Kim, T. Y. (2013) Loss of extracellular superoxide dismutase induces severe IL-23-mediated skin inflammation in mice. *J. Invest. Dermatol.* **133**, 732–741
84. Grommes, J., and Soehnlein, O. (2011) Contribution of neutrophils to acute lung injury. *Mol. Med.* **17**, 293–307
85. Segel, G. B., Halterman, M. W., and Lichtman, M. A. (2011) The paradox of the neutrophil’s role in tissue injury. *J. Leukoc. Biol.* **89**, 359–372
86. Faraci, F. M., and Didion, S. P. (2004) Vascular protection. Superoxide dismutase isoforms in the vessel wall. *Arterioscler. Thromb. Vasc. Biol.* **24**, 1367–1373
87. Batinić-Haberle, I., Rebouças, J. S., and Spasojević, I. (2010) Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. *Antioxid. Redox Signal.* **13**, 877–918
88. Jiang, F., Zhang, Y., and Dusting, G. J. (2011) NADPH oxidase-mediated redox signaling. Roles in cellular stress response, stress tolerance, and tissue repair. *Pharmacol. Rev.* **63**, 218–242
89. Phillipson, M., and Kubes, P. (2011) The neutrophil in vascular inflammation. *Nat. Med.* **17**, 1381–1390
90. Bedard, K., and Krause, K. H. (2007) The NOX family of ROS-generating NADPH oxidases. Physiology and pathophysiology. *Physiol. Rev.* **87**, 245–313